landiolol

Known as: (-)-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methyl p-((S)-2-hydroxy-3-((2-(4-morpholinecarboxamido)ethyl)amino)propoxy)hydrocinnamate 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2017
0102019992017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
PURPOSE Postoperative atrial fibrillation (AF) is a common complication of cardiac surgery that is associated with an increased… (More)
Is this relevant?
2012
2012
BACKGROUND Recent studies have suggested that esmolol is the first choice for rate control in patients with postoperative atrial… (More)
Is this relevant?
2011
2011
OBJECTIVE Atrial fibrillation occurs frequently after cardiac surgery and not only prolongs hospitalization but also influences… (More)
Is this relevant?
2009
2009
Previous studies suggest that the blockade of beta-adrenoceptors augments the release of inflammatory regulators in response to… (More)
Is this relevant?
2007
2007
BACKGROUND The ultra-short-acting beta1-selective blocker, landiolol, is widely used in Japan. We investigated the effects of… (More)
Is this relevant?
2005
2005
The objective of this prospective study was to compare the cardiovascular responses with or without landiolol to the induction of… (More)
  • table 1
  • figure 1
  • table 3
Is this relevant?
2005
2005
In this randomized, double-blind, controlled study, we tested the hypothesis that the short-acting beta(1)-adrenoceptor… (More)
Is this relevant?
2005
2005
PURPOSE Several ss-adrenergic-blocking drugs have been used during electroconvulsive therapy (ECT) to stabilize the hemodynamic… (More)
Is this relevant?
2003
2003
PURPOSE Beta blockers are thought to exert beneficial effects on the ischemic heart. The authors examined the effects of… (More)
Is this relevant?
2001
2001
PURPOSE To compare the cardiovascular and sympathetic effects of a new ultra-short-acting, highly cardioselective beta- blocker… (More)
Is this relevant?